Overview: Vesselon’s Transformative Co-formulation Method

By Clayton Larsen — President & CEO, Vesselon Inc.

Vesselon has pioneered a revolutionary co-formulation method that not only enhances drug bioavailability but also creates a new patentable entity for each drug without modifying its active compound. Utilizing our Imagent® lipid microspheres — originally FDA-approved for contrast ultrasound — Vesselon’s TriForm™ co-formulation encapsulates drugs in ten billion gas microspheres and simultaneously generates fifty trillion drug-encapsulated self-assembling liposomes in the vial. This process, completed on site in just five minutes prior to patient administration, maintains the original molecular mechanism of action of the drug while significantly improving its bioavailability.

Imagent, initially proven as an extraordinarily safe drug through five human trials and sixty-seven animal studies supporting its NDA filing, becomes a versatile co-formulation agent when combined with various therapeutic drugs. The co-formulated drug, still in its unaltered state, proves to have equal, if not lower, toxicity profiles when compared to individual drug administration.

The administration process involves using common diagnostic ultrasound at FDA-cleared levels for less than 10 minutes, targeting the tissue of interest. This interaction with the microspheres initiates sonoporation — a process where nanoscale pores open in the endothelial wall, facilitating increased drug entry into the target tissue. However, sonoporation is just one facet of the multiple modes of action occurring simultaneously at the cellular level.

Vesselon’s innovative approach fundamentally changes the receive characteristics of tissue, going beyond being a mere drug delivery platform. The increased biodistribution of the therapeutic drug, coupled with the tissue modulation effects, aims to establish a new efficacy baseline, setting a standard that other molecules in the same class cannot easily compete with.

Driven by the transformative potential of this cutting-edge co-formulation method, we believe that our platform can produce multiple billion-dollar drug co-formulations before 2030.

Vesselon develops patentable drug co-formulations using an FDA-approved, biophysically activated lipid microsphere and self-assembling liposomes. These co-formulations safely make targeted tissues more receptive to therapeutic drugs, producing unprecedented levels of efficacy. View our live town hall event to learn more at www.vesselon.com/townhall.